CMC Biologics Announces New General Manager of Copenhagen Facility

- Strategic hire to support the ongoing focus on creating a world-class, commercial manufacturing facility

COPENHAGEN, Denmark and SEATTLE, Aug. 30, 2012 /PRNewswire/ -- CMC Biologics, a leading contract manufacturing organization known for its technical excellence in process development and cGMP manufacture, today announced that it has hired Patricio E. Massera to serve as the Company's new General Manager for its Copenhagen facility. Mr. Massera will manage the day to day site operations of CMC Biologics' world-class commercial manufacturing facility, including research and development, manufacturing, quality operations, and supply chain management.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"We welcome Patricio's experience and leadership to our team," said Gustavo Mahler, Global Chief Operations Officer of CMC Biologics. "His breadth of expertise in biopharmaceutical manufacturing and process improvement will be instrumental as we continue to prepare the Copenhagen manufacturing operation for commercial regulatory approval."

"CMC Biologics is a promising and rapidly growing organization with broad capabilities in clinical and commercial manufacture," said Massera. "I am pleased to join this dedicated team of people, and I look forward to the opportunities and successes ahead."

Mr. Massera brings more than 15 years of senior biopharmaceutical industry expertise in manufacturing of biological processes, GMP process and quality systems auditing and validation, and strategic and financial planning.

About CMC Biologics

CMC Biologics is a global contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world from its facilities in Europe and the USA. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. CMC Biologics is located in Copenhagen, Denmark; Seattle, Washington; and Berkeley, California. More detailed information can be found at www.cmcbiologics.com.